C4 Therapeutics Reports Promising Phase 1 Clinical Trial Results for Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at ASH Annual Meeting
Cemsidomide shows promising response rates in multiple myeloma and non-Hodgkin's lymphoma, with manageable safety profiles.Quiver AI SummaryC4 Therapeutics, Inc. presented promising clinical data at the...
Unusual Options Activity: Strategies for Success with Three Single-Letter Stocks
Hidden within Wednesday’s 1,211 unusually active options were 22 calls and puts whose stock symbols have a single letter. It might not seem like a great investment strategy, but single-letter stocks...
C4 Therapeutics Appoints Steve Hoerter to Board of Directors to Strengthen Oncology Expertise
C4 Therapeutics appoints Steve Hoerter to its Board, enhancing oncology expertise to advance targeted protein degradation innovations.Quiver AI SummaryC4 Therapeutics, Inc. has announced the appointment...